FDA to encourage development of nonopioid pain therapies

The FDA is taking steps to encourage drug manufacturers to pursue the creation of nonaddictive opioid alternatives for pain management, according to The Washington Post.

As part of this effort, the agency will withdraw its 2014 guidance to the drug industry on pain medications, which, in some instances, acts as a barrier to new drug products, according to FDA commissioner Scott Gottlieb, MD.

Over the next year, the FDA aims to issue numerous documents to spur pain drug development through smaller clinical trials, faster approvals and quicker drug launches.

The FDA will provide advisories to drug companies, informing them what the FDA is looking for in nonopioid medications for chronic pain. Another committee will show manufacturers how to reduce patient exposure to opioids, and a third is set to update drugmakers on the risk of illicit drug use.

FDA officials hope these new advisories will act as road maps to bring nonopioid pain medications to the market, while encouraging drug companies to focus more intently on the nonopioid pain medication field.

More articles on opioids: 

FDA targets 21 websites selling illegal opioids

Viewpoint: Trump administration should follow states' lead in opioid epidemic response

Rhode Island Hospital secures $11.8M grant to create opioid research center

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars